Inbar Agmon Nardi1,2, Zaza Iakobishvili3,4. 1. Department of Internal Medicine F (Recanati), Rabin Medical Center-Beilinson, Petah Tikva, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. zaza@013.net. 4. Department of Cardiology, Holon Medical Center, Clalit Health Services, Tel Aviv, Israel. zaza@013.net.
Abstract
PURPOSE OF REVIEW: As the number of cancer survivors continues to rise with improved early-detection methods and advancing therapies, along with it, there come adverse health outcomes as a result of physiological and psychological effects of cancer, as well as adverse effects of cancer treatment itself. This paper reviews the risk of cardiovascular disease in cancer survivors. RECENT FINDINGS: Cancer survivors are at higher risk of having modifiable cardiovascular (CV) risk factors, such as hypertension, diabetes mellitus, obesity, tobacco smoking, and physical inactivity. Cardiotoxicity is a well-established adverse effect of various anticancer regimens, which further elevates the cardiovascular risk in cancer patients. The increased risk of CVD and CVD-related death in cancer survivors is likely to be multifactorial, involving cardiotoxic effects of cancer treatments as well as comorbidities and harmful lifestyle habits. Targeting and managing known cardiac risk factors should be a main target in CVD prevention in cancer survivors.
PURPOSE OF REVIEW: As the number of cancer survivors continues to rise with improved early-detection methods and advancing therapies, along with it, there come adverse health outcomes as a result of physiological and psychological effects of cancer, as well as adverse effects of cancer treatment itself. This paper reviews the risk of cardiovascular disease in cancer survivors. RECENT FINDINGS:Cancer survivors are at higher risk of having modifiable cardiovascular (CV) risk factors, such as hypertension, diabetes mellitus, obesity, tobacco smoking, and physical inactivity. Cardiotoxicity is a well-established adverse effect of various anticancer regimens, which further elevates the cardiovascular risk in cancerpatients. The increased risk of CVD and CVD-related death in cancer survivors is likely to be multifactorial, involving cardiotoxic effects of cancer treatments as well as comorbidities and harmful lifestyle habits. Targeting and managing known cardiac risk factors should be a main target in CVD prevention in cancer survivors.
Entities:
Keywords:
Cancer treatment; Cardio-oncology; Cardiovascular disease in cancer
Authors: Jesse M Bijl; Marleen M Roos; Elena M van Leeuwen-Segarceanu; Josephine M Vos; Willem-Jan W Bos; Douwe H Biesma; Marco C Post Journal: Am J Cardiol Date: 2015-12-07 Impact factor: 2.778
Authors: Elisé G Kaboré; Charles Guenancia; Ines Vaz-Luis; Antonio Di Meglio; Barbara Pistilli; Charles Coutant; Paul Cottu; Anne Lesur; Thierry Petit; Florence Dalenc; Philippe Rouanet; Antoine Arnaud; Olivier Arsene; Mahmoud Ibrahim; Johanna Wassermann; Geneviève Boileau-Jolimoy; Anne-Laure Martin; Jérôme Lemonnier; Fabrice André; Patrick Arveux Journal: PLoS Med Date: 2019-12-23 Impact factor: 11.069